Stoke Therapeutics, Inc.

NasdaqGS:STOK Rapporto sulle azioni

Cap. di mercato: US$781.3m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Stoke Therapeutics Dividendo

Dividendo criteri di controllo 0/6

Stoke Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore2.0%
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Utile per azione-US$1.97
Previsione del rendimento del dividendo a 3 anni0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Jul 22
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 14

It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

May 30
It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

Apr 04

Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

Mar 21
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Dec 07
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

May 09
Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

May 06
Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

May 02
Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Dec 13
We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Aug 14
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M

Aug 08

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Apr 29
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

Jan 13
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Jun 16
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS misses by $0.02

May 10

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap

Dec 14

Stoke Therapeutics prices $97.5M public offering

Nov 20

Stoke Therapeutics -2.7% AH, proposes public offering

Nov 18

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Nov 18
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di STOK siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di STOK siano aumentati.


Rendimento dei dividendi rispetto al mercato

Stoke Therapeutics Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di STOK rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (STOK)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.5%
Media del settore (Biotechs)2.0%
Previsione dell'analista in 3 anni (STOK)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di STOK rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di STOK rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.


Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di STOK per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.


Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché STOK non ha segnalato alcun pagamento.


Scoprire le società che pagano dividendi forti